Intended effect or side effect?
Regulators record the same experience in different places. The US label does not include decreased appetite in Table 3, its list of common injection reactions, and says the tablet trial showed similar types and frequencies of common reactions [1]. The European table of adverse reactions for the tablet leaves it out as well, while its pharmacology section describes less hunger and lower intake as part of how semaglutide acts [2]. Trial investigators, by contrast, log anything a participant reports, so appetite loss appears in the registry results [4].
| Source | What it reports | Comparison |
|---|---|---|
| US label, sections 6.1 and 12.2 [1] | Not listed as a reaction; calorie intake falls, likely through appetite | No tablet rate |
| EU tablet SmPC, sections 4.8 and 5.1 [2] | Not in the adverse reaction table; less hunger, fewer cravings, lower intake | No rate |
| OASIS 4 registry, 25 mg tablet, weeks 0–71 [4] | 14 of 204 people (6.9%) | 1 of 102 on placebo (1.0%) |
| OASIS 1 registry, 50 mg oral semaglutide, weeks 0–75 [6] | 56 of 334 people (16.8%) | 24 of 333 on placebo (7.2%) |
What the tablet trials can and cannot show
OASIS 4 is the trial behind the US tablet approval: adults without diabetes, randomized two to one to 25 mg tablets or placebo for 64 weeks, with weight falling 13.6% against 2.2% [1][3]. The registry counts people who reported decreased appetite at any point; it does not say how long it lasted, how severe it was or whether anyone stopped because of it [4].
OASIS 1 tested a higher 50 mg dose for 68 weeks, and the share reporting decreased appetite was larger in both arms [5][6]. Because the doses, durations and populations differ, the two trials are best read side by side rather than as a dose comparison.
Appetite studies of oral semaglutide
Two small, sponsor-funded studies measured eating directly rather than relying on reported side effects. In adults with obesity taking oral semaglutide escalated to 50 mg, energy intake at a lunch where they could eat as much as they liked fell by 39.2 percentage points more than on placebo after 20 weeks; participants reported less hunger, more fullness, fewer cravings and better control of eating [7].
In 15 people with type 2 diabetes on oral semaglutide escalated to 14 mg, a Rybelsus® dose rather than a Wegovy® one, total intake over a day of free meals was 38.9% lower than on placebo after 12 weeks, with fewer cravings and better eating control [8]. Neither study used the 25 mg Wegovy® tablet, so they describe the molecule taken by mouth rather than this exact product.
Why appetite falls
What the labels support: semaglutide activates GLP-1 receptors, and GLP-1 regulates appetite and calorie intake through receptors in brain areas involved in eating [1]. Europe adds that it acts on areas linked to both hunger and food reward and reduces the preference for high-fat foods [2].
What is less settled: the US label says semaglutide delays stomach emptying [1], yet the 50 mg oral study found no significant difference in stomach emptying at week 20 using a paracetamol test [7]. A fuller stomach may play a part early on, but the studies point mostly to the brain’s appetite signals.
General background: MedlinePlus notes that any illness can dull appetite and that it usually returns when the illness resolves [10].
When eating very little becomes a concern
The Wegovy® documents set no minimum intake, but several of their warnings become more relevant when food and drink drop sharply [1].
- Fluids: the Medication Guide links nausea, vomiting and diarrhea to dehydration that can harm the kidneys, and says drinking fluids helps lower that chance [1].
- Blood sugar: in type 2 diabetes, insulin or a sulfonylurea raises the risk of low blood sugar, and section 5.4 says prescribers may lower those doses [1].
- Gallbladder: section 5.3 says substantial or rapid weight loss can increase the risk of gallstones [1].
- Other weight-loss products: Europe does not recommend semaglutide with other products for weight management, as that use has not been studied [2].
Other reasons appetite can drop
Low appetite on the tablet is not always the medicine. MedlinePlus lists sadness, depression or grief, chronic liver, kidney, lung or heart disease, an underactive thyroid, early pregnancy and some medicines, including certain antibiotics and opioid painkillers [10]. Nausea can also pass for low appetite; the Wegovy® tablets nausea page covers it separately.
MedlinePlus advises seeking medical help when low appetite comes with signs of depression, drug or alcohol use or an eating disorder [10].
The morning routine and the first meal
The tablet sets rules about timing, not portions. The US label places the tablet first thing in the morning on an empty stomach, followed by a gap of at least half an hour with no food, drink or other oral medicines; Europe adds a fasting period of at least eight hours before the dose [1][2]. Neither document says anything about skipping breakfast or how much to eat once the 30 minutes have passed, so meal planning on low-appetite days is a question for your prescriber or a dietitian.
What may help, according to the sources
- Novo Nordisk’s Wegovy® side-effect page suggests asking your healthcare professional whether smaller, more frequent meals would help, whether to eat slowly and stop when full, and how to stay hydrated without feeling too full [9].
- MedlinePlus suggests a diet history: writing down everything you eat and drink for 24 hours or more [10].
- If a medicine seems to be taking your appetite away, MedlinePlus says to ask your provider about the dose or the medicine rather than stopping it yourself [10].
- Tell your provider about all other medicines and supplements, as the Medication Guide asks; because Wegovy® slows the stomach, it may change how quickly some other medicines are absorbed [1].
Wegovy®, Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that will not go away, with or without vomiting, possibly reaching the back | Stop Wegovy® and call your healthcare provider straight away | Emergency | Medication Guide [1] |
| Eating and drinking so little that nausea, vomiting or diarrhea is not settling | Your healthcare provider right away | Today | Medication Guide [1] |
| Shakiness, sweating, hunger or confusion while on insulin or a sulfonylurea | Follow your low blood sugar plan, then contact your diabetes team | Today | Medication Guide [1] |
| Low appetite together with low mood, alcohol or drug use, or signs of an eating disorder | Your healthcare provider | Today | MedlinePlus [10] |
| Upper stomach pain, fever, yellow skin or eyes, or clay-coloured stools | Your healthcare provider | Today | Medication Guide [1] |
| Low appetite that bothers you or makes regular meals hard | Your prescriber | At your next appointment | Medication Guide [1] |
